Bipolar Disorder and Addiction: Signs, Risks, and Integrated Treatment
Plain, fact-first answers about how care works here. Want to talk to a person? Call (888) 464-2144.
- The Archangel Centers is a licensed outpatient addiction treatment provider.
- The Archangel Centers operates clinics in Tinton Falls, NJ and Charlotte, NC.
- Bipolar disorder with co-occurring substance use disorder is part of the outpatient continuum at The Archangel Centers.
- Bipolar disorder and substance use disorder are treated together in an integrated dual-diagnosis treatment plan.
- Integrated dual-diagnosis care is delivered by the same clinical team from intake.
- Medication-assisted treatment (MAT) includes Suboxone, Vivitrol, and Sublocade.
- The Archangel Centers works with most major commercial insurance plans with free benefits verification.
Bipolar disorder is a chronic mood disorder defined by distinct episodes of elevated mood (mania or hypomania) and depressive episodes. It co-occurs with substance use disorder (SUD) at rates substantially higher than the general population: lifetime SUD prevalence among adults with bipolar I is roughly 60 percent in epidemiologic samples, the highest comorbidity of any Axis I mood disorder. Alcohol and stimulants are the most common substances, but opioids, benzodiazepines, and cannabis use also occur frequently.
The overlap is not coincidence. The same neurobiology that produces episode-level mood swings — disruptions in dopaminergic and serotonergic regulation, sleep-wake architecture, and reward processing — also creates vulnerability to substances that act on those systems. Each condition complicates the other: substance use can trigger mood episodes, mood episodes drive substance use, and the combined picture is more disabling than either condition alone.
This guide explains what bipolar disorder is in clinical terms, how mood episodes and substance use interact, what untreated co-occurring bipolar and SUD looks like, and what evidence-based integrated treatment looks like. This page is informational. If you are looking for treatment, see the levels of care section, or call (888) 464-2144 to speak with admissions at The Archangel Centers.
What bipolar disorder is
In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the American Psychiatric Association organizes bipolar and related disorders by the type and duration of mood episodes the person has experienced. Lifetime prevalence of bipolar spectrum disorders is approximately 4.4 percent of U.S. adults.
Three primary diagnoses define the spectrum:
Bipolar I disorder
Bipolar I requires at least one full manic episode lasting seven days or longer (or any duration if hospitalization is required). Manic episodes involve abnormally elevated, expansive, or irritable mood plus increased energy, alongside symptoms such as inflated self-esteem or grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, increased goal-directed activity, and excessive involvement in high-risk activities. Most people with bipolar I also experience depressive episodes, though a depressive episode is not required for the diagnosis.
Bipolar II disorder
Bipolar II requires at least one hypomanic episode (four days or longer of the same mood elevation symptoms as mania, but less severe and without psychosis or hospitalization) plus at least one major depressive episode. Bipolar II is not "mild bipolar." Depressive episodes in bipolar II are often longer and more disabling than the hypomanic ones, and suicide risk is comparable to bipolar I.
Cyclothymic disorder
Cyclothymia involves at least two years (one in adolescents) of numerous periods of hypomanic symptoms and depressive symptoms that do not meet full criteria for hypomania or major depression. The pattern is chronic, fluctuating, and often missed because no single episode looks severe enough to warrant assessment.
What separates bipolar from unipolar depression
A common clinical scenario: a person enters treatment for what looks like recurrent depression, sometimes after years of failed antidepressant trials, and a careful history reveals past hypomanic episodes that were never identified as such. The hypomania felt good — high energy, productivity, sociability — so the person never sought help for it. Only the depressive phases brought them to care.
The distinction matters for treatment. Antidepressants alone, without a mood stabilizer, can induce manic or hypomanic episodes in people with underlying bipolar disorder, and can accelerate the natural cycling frequency. This is why a thorough mood history precedes medication recommendations, and why bipolar disorder is one of the most common reasons that depression treatment fails. See depression and addiction for the unipolar picture.
How bipolar disorder and substance use interact
The relationship between bipolar disorder and SUD is bidirectional, and it shifts by mood phase. Patterns clinicians see most often:
Depressive-phase use: self-soothing
During depressive episodes, alcohol and opioids are commonly used to dull the experience of low mood, anhedonia, hopelessness, and intrusive thoughts. The relief is short-term; the substances themselves are depressants and ultimately deepen the depressive episode. Sedative-hypnotic use (benzodiazepines, alcohol at night) often emerges around sleep disturbance, which is a core feature of depressive episodes.
Manic and hypomanic-phase use: amplification and impulsivity
During elevated phases, the same person who drank to numb a depression may use stimulants (cocaine, methamphetamine, prescription stimulants) or alcohol socially in ways that feel additive to the mood. Manic and hypomanic episodes feature reduced inhibition, impulsivity, and high-risk decision-making, all of which lower the threshold for substance use. Many people experience their heaviest substance use during elevated episodes, and the consequences (financial, legal, interpersonal) often surface during the subsequent depressive crash.
Substances as episode triggers
Substance use can directly trigger mood episodes. Stimulants and cocaine can precipitate manic or hypomanic episodes in vulnerable individuals. Alcohol withdrawal can trigger depressive symptoms. Sleep disruption from any substance can destabilize mood, and sleep loss is the most reliable known trigger of manic episodes. Cannabis use is associated with earlier age of onset and more frequent episodes in longitudinal studies.
Signs and symptoms of co-occurring bipolar and SUD
The clinical picture of co-occurring bipolar and SUD is rarely tidy. A clinician puts the pattern together over time. Common signs:
- Distinct mood episodes — periods of clear depression alternating with periods of elevated mood, energy, or irritability — co-occurring with substance use that has become difficult to stop
- Substance use that intensifies during specific mood phases, rather than being constant across time
- A pattern of "feeling great, then crashing" that has cycled multiple times across years
- Reduced need for sleep, racing thoughts, pressured speech, or unusual goal-directed activity (working through the night, starting many projects) alongside increased substance use
- Major depressive episodes that have not responded to standard antidepressant trials, especially if past elevated periods were dismissed as "just being productive"
- Family history of bipolar disorder, severe depression, suicide, or psychiatric hospitalization
- Impulsive decisions during elevated phases — high-risk spending, sexual behavior, business ventures, or substance use — that the person later finds difficult to explain
- Substance-induced mood episodes, including stimulant-induced mania or alcohol-withdrawal-induced depression
- Repeated psychiatric hospitalizations, ER visits for suicidal ideation, or substance-related crises
The risks of untreated bipolar in addiction recovery
Bipolar disorder is one of the most lethal psychiatric conditions, and untreated bipolar in the context of active SUD compounds the risk. The clinical concerns:
Suicide
Bipolar disorder carries the highest suicide risk of any mood disorder. Lifetime suicide rates in bipolar populations are estimated at 6 to 7 percent, with attempts substantially more common. Risk is highest during depressive and mixed episodes, in the first years after diagnosis, and when SUD co-occurs. Lithium uniquely reduces suicide risk in bipolar disorder; the Cipriani 2013 BMJ meta-analysis found lithium associated with reduced suicide death and self-harm compared with placebo and other mood stabilizers. Safety planning is a core part of treatment from day one.
Relapse cycles
When bipolar disorder is untreated, depressive and elevated episodes continue to occur, and each episode is a high-risk window for substance use relapse. Recovery built only on the substance-use side, without mood stabilization, often holds for weeks or months and then collapses during the next mood episode. This is why "get sober first, then address the mood" fails for most people with co-occurring bipolar and SUD.
Rapid cycling
Some people develop rapid cycling, defined as four or more mood episodes in a year. Rapid cycling is associated with substance use, antidepressant exposure without a mood stabilizer, thyroid dysfunction, and is harder to treat than non-rapid-cycling bipolar. Identifying rapid cycling changes the medication strategy.
Hospitalizations and functional impairment
Severe manic episodes, psychotic features, or acute suicidal ideation may require inpatient psychiatric hospitalization. Untreated bipolar disorder produces cumulative impairment across work, relationships, and finances, and each episode can leave functional ground that is hard to recover.
Treatment levels of care
Evidence-based treatment for co-occurring bipolar disorder and SUD is matched to current mood severity, functional impairment, and risk. The American Society of Addiction Medicine (ASAM) and the Level of Care Utilization System (LOCUS) describe a continuum of outpatient care that scales from light-touch counseling to full-day clinical programming. For acute manic episodes, severe suicidal ideation, or psychiatric crisis that exceeds outpatient scope, inpatient psychiatric stabilization is coordinated with partner hospitals before outpatient programming begins.
The most common outpatient levels:
| Level | What it looks like | Who it's for |
|---|---|---|
| Outpatient (OP) | Individual therapy, periodic groups, periodic medical follow-up | Stable mood, continuing-care phase, step-down from higher level |
| Intensive Outpatient (IOP) | 3 or 5 days per week, 3 clinical hours each | Moderate mood and SUD symptoms, or step-down from Partial Care |
| Partial Care / Day Treatment (NJ) | Full clinical day, up to 6 days per week | Significant functional impairment, recent episode, dual-diagnosis presentation |
| Virtual treatment (NJ residents only) | Secure video sessions | Clients who meet criteria and have safe home environment |
| Inpatient psychiatric hospitalization | Live-in psychiatric setting | Acute mania, psychosis, or imminent suicide risk (coordinated with partner hospitals) |
Therapy approaches with the strongest evidence
A number of therapy modalities have well-documented effectiveness for bipolar disorder, and the same modalities — adapted — address co-occurring SUD. Most integrated programs combine several.
- **Cognitive behavioral therapy (CBT)** addresses the depressive thought patterns that drive low-phase substance use, and also the cognitive distortions of elevated phases (grandiosity, invincibility, urgency) that drive impulsive use. CBT also targets the substance-use cues themselves.
- **Dialectical behavior therapy (DBT)** is particularly well-suited to bipolar disorder because emotion regulation and distress tolerance are core skill deficits across mood phases. DBT skills also support the moment-to-moment work of staying sober during a mood episode.
- Motivational interviewing (MI) is essential for medication adherence. Discontinuation of mood stabilizers — often when the person feels well and questions whether they still need medication — is one of the most common drivers of relapse. MI addresses ambivalence directly.
- Family-focused psychoeducation has strong clinical support for reducing relapse in bipolar disorder. Family members learn to identify early warning signs, support medication adherence, and respond to mood episodes constructively. Family work is conducted under signed release.
- Trauma-informed therapy is provided in individual therapy for clients whose presentation includes trauma. Bipolar disorder and trauma frequently co-occur, and trauma-informed work is integrated into the dual-diagnosis plan rather than delivered as a separate track.
Medication considerations
Medication is central to bipolar treatment in a way that is not always true for other mood conditions. For most people with bipolar I, and for many with bipolar II, sustained recovery depends on a working medication regimen. Medication decisions are individualized, made collaboratively between the client and the on-site medical provider, and revisited as the picture evolves.
Mood stabilizers
The core class. Lithium is the longest-studied mood stabilizer and is the only psychiatric medication with consistent evidence for reducing suicide death and self-harm in bipolar populations (Cipriani 2013, BMJ meta-analysis). Lithium requires periodic blood-level monitoring and renal and thyroid function checks, but for many people it is the single most effective medication available. Valproate (Depakote) is effective for acute manic episodes and maintenance, and is often used when lithium is not tolerated. Lamotrigine is particularly effective for the depressive pole of bipolar II and is generally well-tolerated, though it requires slow titration to reduce rash risk.
Atypical antipsychotics
Several atypical antipsychotics are FDA-approved for bipolar disorder, both for acute episodes and maintenance, used alone or alongside mood stabilizers. Decisions about which agent to use depend on the client's mood pattern, side-effect profile, and prior medication history.
Antidepressants — used cautiously
Antidepressants alone, without a mood stabilizer, can induce manic or hypomanic episodes in bipolar disorder and can accelerate cycling frequency. When antidepressants are used in bipolar disorder, they are generally used alongside a mood stabilizer, and the medical provider monitors for signs of induced elevation.
MAT for co-occurring SUD
For clients with co-occurring opioid use disorder, the medication-assisted treatment formulary includes Suboxone (buprenorphine/naloxone, primary), Vivitrol (naltrexone, long-acting injectable), and Sublocade (buprenorphine extended-release injectable). Methadone is not used in our formulary; clients best served by methadone are referred to a federally licensed opioid treatment program. For alcohol use disorder, naltrexone (oral or Vivitrol) is used. MAT is layered into the psychiatric medication plan, with attention to interactions and to the client's overall medication burden.
What recovery from co-occurring bipolar and SUD looks like
There is no single picture of recovery from co-occurring bipolar and SUD. The work is long. Most people who recover do so over years, with episodes along the way, and with support from a combination of medication management, therapy, peer community, family involvement, and ongoing self-care. Recovery is not the absence of mood episodes. It is the presence of a structure that catches them earlier, treats them faster, and keeps substance use out of the equation.
What predicts a sustainable recovery:
- Medication adherence as the central, non-negotiable work — particularly for bipolar I
- Sleep regularity treated as a clinical priority, not a lifestyle preference (sleep loss is the most reliable trigger of manic episodes)
- Early-warning sign awareness, with personal indicators identified, written down, and shared with at least one family member or close contact under release
- Substance use addressed in the same plan as the mood disorder, by the same team, rather than sequentially
- A continuous relationship with a clinical team and an on-site or outpatient medical provider, not a one-time program
- Family involvement where the family is willing and the client consents
- Safety planning that is revisited rather than written once and filed
- Time. Mood stabilization takes weeks to months. Skill internalization takes longer.
Frequently Asked Questions
How do I know I need bipolar and addiction treatment?
Will I need a mood stabilizer?
What if I have a manic episode during treatment?
What if I'm suicidal?
What about hospitalization?
Will treatment interfere with work?
Can my family participate?
Is methadone available?
How long is treatment?
Admissions are confidential and staffed 24/7 at (888) 464-2144. Or browse a specific clinic page for hours, address, and the full program.